Reuters -- Investors could shave off a third of the valuation of Valeant Pharmaceuticals International (VRX.N) if its prospective epilepsy drug retigabine fails to live up to expectations, according to a Barron’s report.
Reuters -- Investors could shave off a third of the valuation of Valeant Pharmaceuticals International (VRX.N) if its prospective epilepsy drug retigabine fails to live up to expectations, according to a Barron’s report.
